Tandem Diabetes Care reported a 48% increase in sales to $97.9 million and a gross margin of 51% for the first quarter of 2020. Worldwide pump shipments increased by 18% compared to the same period in 2019. However, due to the COVID-19 pandemic, the company withdrew its full-year financial guidance.
Worldwide pump shipments increased 18 percent to 17,378 pumps.
Sales increased 48 percent to $97.9 million.
Gross margin was 51 percent for both periods.
Adjusted EBITDA improved to 4 percent of sales.
For the quarter ending June 30, 2020, sales are estimated to be at least $85 million, including international sales of approximately $10 million. For the year ending December 31, 2020, the Company has withdrawn its financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance